Pharmacokinetics, absolute bioavailability and excretion balance after a single oral dose and IV microtracer dose of [14C]ODM-111; an open-label, non-randomised, single centre study in healthy male subjects
Latest Information Update: 06 Nov 2024
At a glance
- Drugs JMKX 000623 (Primary)
- Indications Neuropathic pain
- Focus Pharmacokinetics
- 29 Oct 2024 According to an Orion media release, in October, the company decided to terminate the ODM-111 development program. Recent findings from a non-clinical toxicology study indicated that the profile of ODM-111 does not support long-term use of the molecule. Altogether we consider the therapeutic window of ODM-111 too narrow, and thus it is not feasible for Orion to continue the development program but rather focus on other promising programs in our pipeline.
- 29 Oct 2024 Status changed from recruiting to discontinued, according to an Orion media release.
- 31 Jul 2024 New trial record